The shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) currently has mean rating of 1.80 while 1 analysts have recommended the shares as “BUY”, 4 recommended as “OUTPERFORM” and 0 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.
The company’s mean estimate for sales for the current quarter ending Jun 16 is 240.00K by 3 analysts. The means estimate of sales for the year ending Dec-16 is 980.00K by 3 analysts.
The mean price target for the shares of Abeona Therapeutics Inc. (ABEO) is at 12.63 while the highest price target suggested by the analysts is 17.00 and low price target is 6.00. The mean price target is calculated keeping in view the consensus of 4 brokerage firms.
The average estimate of EPS for the current fiscal quarter for Abeona Therapeutics Inc. (ABEO) stands at -0.15 while the EPS for the current year is fixed at -0.59 by 3 analysts.
The next one year’s EPS estimate is set at -0.42 by 3 analysts while a year ago the analysts suggested the company’s EPS at -0.59.
In its latest quarter ended on 31st March 2016, Abeona Therapeutics Inc. (ABEO) reported earnings of $-0.17. The posted earnings missed the analyst’s consensus by $-0.04 with the surprise factor of -30.38%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.
On May 24, 2016 Abeona Therapeutics Inc. (ABEO) announced the FDA has allowed an Investigational New Drug (IND) Application for its Phase 1/2 Clinical Study with gene therapy candidate ABO-101 (AAV-NAGLU) for patients with Sanfilippo syndrome type B (MPS IIIB) to be conducted at Nationwide Children’s Hospital (Columbus, OH). This is the second FDA allowance for a gene therapy trial from Abeona this year, following allowance of an IND in February for ABO-102, for patients with MPS IIIA which commenced with dosing of the first cohort of patients this month.